Entrada Therapeutics (TRDA) Other financing activities (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Other financing activities of $100000.0 for Q1 2026, down 71.43% year-over-year from $350000.0 in Q1 2025, and up 19.05% quarter-over-quarter from $84000.0 in Q4 2025.
Entrada Therapeutics (TRDA) Other financing activities (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Other financing activities history runs 7 years deep, the most recent figure standing at $100000.0 for Q1 2026.
- In Q1 2026, Other financing activities fell 71.43% year-over-year to $100000.0; the TTM figure through Mar 2026 stood at $212000.0 (down 70.47% YoY), while the FY2025 annual figure was $462000.0, down 19.51% from the prior year.
- Other financing activities for Q1 2026 stood at $100000.0, up from $84000.0 in the prior quarter.
- The five-year high for Other financing activities was $1.1 million in Q2 2024, with the low at -$1.0 million in Q3 2024.
- The 5-year median for Other financing activities is $100000.0 (2026), against an average of $104352.9.
- Peak annual rise in Other financing activities reached 614.0% in 2023, while the deepest fall reached 520.27% in 2023.
- Entrada Therapeutics' Other financing activities stood at $74000.0 in 2022, then tumbled by 520.27% to -$311000.0 in 2023, then surged by 200.0% to $311000.0 in 2024, then tumbled by 72.99% to $84000.0 in 2025, then advanced by 19.05% to $100000.0 in 2026.
- Business Quant data shows TRDA's Other financing activities at $100000.0 in Q1 2026, $84000.0 in Q4 2025, and $8000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Entrada Therapeutics | 290.47 Mn | 290.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 220,000.00 |
| Jun 30, 2026 | 220,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 84,000.00 |
| Dec 31, 2025 | 84,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Mar 31, 2025 | 350,000.00 |
| Mar 31, 2025 | 350,000.00 |
| Dec 31, 2024 | 311,000.00 |
| Dec 31, 2024 | 311,000.00 |
| Sep 30, 2024 | -1.05 Mn |
| Sep 30, 2024 | -1.05 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 206,000.00 |
| Mar 31, 2024 | 206,000.00 |